Septerna (NASDAQ:SEPN – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.15), FiscalAI reports. The company had revenue of $18.88 million during the quarter, compared to analysts’ expectations of $20.78 million. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%.
Septerna Trading Up 1.5%
SEPN traded up $0.74 on Tuesday, hitting $51.48. 43,461 shares of the company’s stock were exchanged, compared to its average volume of 363,903. Septerna has a fifty-two week low of $18.19 and a fifty-two week high of $51.10. The firm has a 50-day moving average price of $39.76 and a 200-day moving average price of $32.71. The stock has a market cap of $2.40 billion, a price-to-earnings ratio of -94.25 and a beta of 2.20.
Insider Activity at Septerna
In other Septerna news, SVP Daniel D. Long sold 3,333 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total transaction of $126,087.39. Following the sale, the senior vice president directly owned 96,412 shares in the company, valued at $3,647,265.96. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $37.41, for a total value of $149,640.00. Following the completion of the transaction, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $6,517,158.69. This trade represents a 2.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 5.80% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
SEPN has been the topic of a number of recent research reports. HC Wainwright raised their price objective on Septerna from $40.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. JonesTrading upped their price target on shares of Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 13th. Stifel Nicolaus upped their target price on Septerna from $49.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday. Raymond James Financial reaffirmed a “strong-buy” rating and set a $49.00 price target on shares of Septerna in a research report on Tuesday, August 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Thursday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.44.
Get Our Latest Analysis on SEPN
About Septerna
Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California.
Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.
Founded in 2021, Septerna has no marketed products; its work is focused on research and clinical development.
Read More
- Five stocks we like better than Septerna
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
